Health & Environmental Research Online (HERO)


Print Feedback Export to File
6115928 
Journal Article 
Review 
Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine 
Herzog, C; Hartmann, K; Künzi, V; Kürsteiner, O; Mischler, R; Lazar, H; Glück, R 
2009 
1 
Vaccine
ISSN: 0264-410X
EISSN: 1873-2518 
27 
33 
4381-4387 
English 
19450630 
WOS:000268217600001 
Since the introduction to the Swiss market in 1997, Crucell (former Berna Biotech Ltd.), has sold over 41 million doses worldwide of the virosomal adjuvanted influenza vaccine, Inflexal V. Since 1992, 29 company sponsored clinical studies investigating the efficacy and safety of Inflexal V have been completed in which 3920 subjects participated. During its decade on the market, Inflexal V has shown an excellent tolerability profile due to its biocompatibility and purity. The vaccine contains no thiomersal or formaldehyde and its purity is reflected in the low ovalbumin content. By mimicking natural infection, the vaccine is highly efficacious. Inflexal V is the only adjuvanted influenza vaccine licensed for all age groups and shows a good immunogenicity in both healthy and immunocompromised elderly, adults and children. This review presents and discusses the experience with Inflexal V during the past decade.